Literature DB >> 23553517

Relation of rheumatoid factor and anti-cyclic citrullinated peptide antibody with disease activity in rheumatoid arthritis: cross-sectional study.

Jung-Yoon Choe1, Jisuk Bae, Hwajeong Lee, Sang-Cheol Bae, Seong-Kyu Kim.   

Abstract

To analyze the association of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (anti-CCP) with non-remission and with disease activity measures in rheumatoid arthritis (RA). Cross-sectional study of consecutive RA patients. Non-remission was defined as a disease activity score (DAS28) ≥ 2.6 at study enrollment. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) were additionally measured. Serum titers of RF and anti-CCP were transformed into incremental levels (100/units) and log-transformed levels. Analysis of association with non-remission was done with logistic regression models, with and without adjustment for age, sex, disease duration, and corticoid use. Multiple regression models, raw and similarly adjusted, were used to measure the association of RF and anti-CCP with the disease activity measures. A total of 385 patients were included, of whom 286 (74 %) were not in remission. Log-transformed RF level was associated with an increased risk of non-remission after adjustment (OR = 1.32, 95 % CI 1.04-1.67). This association was especially evident in patients with less than 10 years of disease duration (OR = 1.51, 95 % CI 1.15-1.99) and in those using steroids (OR = 2.06, 95 % CI 1.22-3.48). Serum RF titers and log-transformed RF levels showed a small but significant association with DAS28 score (adjusted beta coefficients 0.002 and 0.18, respectively; both p ≤ 0.01), but neither with SDAI or CDAI nor with anti-CCP antibody. : Log-transformed RF levels might be associated with non-remission in RA, especially in patients with short disease duration or on steroids.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23553517     DOI: 10.1007/s00296-013-2734-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  23 in total

1.  Transforming data.

Authors:  J M Bland; D G Altman
Journal:  BMJ       Date:  1996-03-23

2.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

3.  The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.

Authors:  H A Chen; K C Lin; C H Chen; H T Liao; H P Wang; H N Chang; C Y Tsai; C T Chou
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

4.  Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort.

Authors:  M Bukhari; M Lunt; B J Harrison; D G I Scott; D P M Symmons; A J Silman
Journal:  Arthritis Rheum       Date:  2002-04

5.  The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis.

Authors:  V F Manfredsdottir; T Vikingsdottir; T Jonsson; A J Geirsson; O Kjartansson; M Heimisdottir; S L Sigurdardottir; H Valdimarsson; A Vikingsson
Journal:  Rheumatology (Oxford)       Date:  2006-01-10       Impact factor: 7.580

6.  The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis.

Authors:  E J Kroot; B A de Jong; M A van Leeuwen; H Swinkels; F H van den Hoogen; M van't Hof; L B van de Putte; M H van Rijswijk; W J van Venrooij; P L van Riel
Journal:  Arthritis Rheum       Date:  2000-08

7.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice.

Authors:  J S Smolen; F C Breedveld; M H Schiff; J R Kalden; P Emery; G Eberl; P L van Riel; P Tugwell
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

8.  Effects of piroxicam and D-penicillamine on T lymphocyte subpopulations, natural killer cells and rheumatoid factor production in rheumatoid arthritis.

Authors:  J Thoen; K Helgetveit; O Førre; Y Haile; E Kåss
Journal:  Scand J Rheumatol       Date:  1988       Impact factor: 3.641

9.  Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.

Authors:  C Alessandri; M Bombardieri; N Papa; M Cinquini; L Magrini; A Tincani; G Valesini
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

10.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.

Authors:  Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen
Journal:  Arthritis Res Ther       Date:  2005-04-07       Impact factor: 5.156

View more
  3 in total

1.  Serum C-Reactive Protein/Albumin Ratio in Rheumatoid Arthritis and its Relationship With Disease Activity, Physical Function, and Quality of Life.

Authors:  İsmihan Sunar; Şebnem Ataman
Journal:  Arch Rheumatol       Date:  2020-02-07       Impact factor: 1.472

2.  Prevalence of selected organ-specific autoantibodies in rheumatoid arthritis and primary Sjögren's syndrome patients.

Authors:  Arkadiusz Koszarny; Maria Majdan; Magdalena Dryglewska; Jacek Tabarkiewicz
Journal:  Reumatologia       Date:  2015-05-18

3.  Fluctuation in anti-cyclic citrullinated protein antibody level predicts relapse from remission in rheumatoid arthritis: KURAMA cohort.

Authors:  Koichi Murata; Hiromu Ito; Motomu Hashimoto; Kosaku Murakami; Ryu Watanabe; Masao Tanaka; Wataru Yamamoto; Shuichi Matsuda
Journal:  Arthritis Res Ther       Date:  2020-11-12       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.